SECRETONEURIN
Fighting the heart failure Pandemic
Welcome to CardiNor
Latest news from CardiNor
July 17th 2025:
CARDINOR IS ACQUIRED BY IC TARGETS AS
IC Targets AS (ICT) has acquired a 92 % stake in CardiNor AS, a Norwegian diagnostics company committed to combating the heart failure (HF) epidemic through its patented blood biomarker, secretoneurin (SN). We see strong synergies between the two companies’ diagnostic solutions for heart failure: CardiNor’s low-cost SN blood test and the proprietary MRI contrast agent mangafodipir from ICT. Elevated SN levels are a strong indicator that cardiac MRI should be performed to assess for structural or functional heart disease.
Newsletter – Cardinor is acquired by IC Targets AS
August 2023:
New publication – secretoneurin provide prognostic information in patients with chronic, stable HF
Secretoneurin (SN) data from the multicenter study GISSI Heart Failure Trial was published in Clinical Biochemistry, volume 118, August 2023.
The study was performed using the CE-marked CardiNor Secretoneurin ELISA Assay.
Background:
Individual patients with chronic heart failure (HF) have very different prognosis, also within subgroups classified according to etiology and left ventricular ejection fraction (LVEF). Circulating protein biomarkers have the potential to identify vulnerable patients that could benefit from special follow-up and uptitration of guideline-directed medical therapy. As B-type natriuretic peptide (BNP)-guided therapy has not demonstrated clear benefit over symptom-based management in major randomized-controlled trial, there is a need to identify additional prognostic biomarkers. Hence, biomarkers that provide incremental prognostic information to BNP, and preferably across the spectrum of LVEF, may prove important for future personalized management strategies in HF patients.
Circulating SN concentrations have been found to provide prognostic information in patients with acute heart failure. In this study plasma SN concentrations were measured at randomisation (n = 1224) and after 3 months (n = 1103) in patients with chronic, stable heart failure from the GISSI-HF study, and the aim was to assess whether SN would improve prognostication also in patients with chronic heart failure.
The authors H. Røsjø, J. Meessen, A. H. Ottesen, R. Latini and T. Omland, on behalf of the GISSI-HF Investigators highlighted that
- SN concentrations separate stable heart failure patients with a poor and favorable prognosis
- SN concentrations were not different between patients with Left Ventricle Ejection Fraction (LVEF) <50% and LVEF ≥50%
- SN concentrations provided additional prognostic information to established risk indices and biomarkers in patients with stable heart failure.
The article is free, very useful and can be downloaded here:
https://www.sciencedirect.com/science/article/pii/S0009912023001145
CardiNor Contact Information
Address
Gaustadalléen 21,
0349 Oslo, Norway